Zsofia K. Stadler

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• Integrated Clinicogenomic Risk Modeling for Metachronous Second Primary Cancers

  medRxiv · 2026-06-22

• Phase 2 study of adjuvant botensilimab in combination with balstilimab in patients with microsatellite-stable colorectal cancer and persistent circulating tumor DNA following surgery and chemotherapy.

  Journal of Clinical Oncology · 2026-05-28

• Genetic testing in endometrial cancer (GenEC): A study on the patient experience with MSK-IMPACT.

  Journal of Clinical Oncology · 2026-05-28

• Implementation of <i>DPYD</i> genotyping in response to FDA black box warning: Initial experience at a comprehensive cancer center.

  Journal of Clinical Oncology · 2026-05-28

• Prevalence, tumor characteristics, and clinical impact of <i>LZTR1</i> pathogenic variants in a large, pan-cancer cohort.

  Journal of Clinical Oncology · 2026-05-27

• Functional assessment of polymerase proofreading variants to define sensitivity to immune checkpoint blockade (ICB) pan-cancer.

  Journal of Clinical Oncology · 2026-05-27

• Expanded germline genetic testing of patients with hematologic malignancies to identify high proportion with hereditary cancer predisposition.

  Journal of Clinical Oncology · 2026-05-27

• Clinical impact of <i>MSH3</i> loss-of-function alterations in patients treated with immune checkpoint blockade across cancer types.

  Journal of Clinical Oncology · 2026-05-27

• A pilot study of a digital, patient-directed consent process for MSK-IMPACT tumor-normal genetic testing in gynecologic cancer.

  Journal of Clinical Oncology · 2026-05-27

• Germline Pathogenic Variants in Homologous Recombination Pathway Genes Are Frequent in Pancreatobiliary Ampullary Carcinoma

  JCO Precision Oncology · 2026-04-01

• Subclinical Telomere Biology Disorder in Cancer Patients Heterozygous for the <scp> <i>RTEL1</i> R1264H </scp> Founder Variant

  American Journal of Medical Genetics Part A · 2025-12-22

• Supplemental Table 1, Supplemental Table 2, Supplemental Table 3, Supplemental Table 6, Supplemental Table 7, Supplemental Figure 1, and Supplemental Figure 2 from Multiple Primary Cancers in Patients Undergoing Tumor-Normal Sequencing Define Novel Associations

  2025-12-17

• Data from Multiple Primary Cancers in Patients Undergoing Tumor-Normal Sequencing Define Novel Associations

  2025-12-17

• Supplemental Materials and Methods from Multiple Primary Cancers in Patients Undergoing Tumor-Normal Sequencing Define Novel Associations

  2025-12-17

• Supplemental Table 4 from Multiple Primary Cancers in Patients Undergoing Tumor-Normal Sequencing Define Novel Associations

  2025-12-17

• Supplemental Table 5 from Multiple Primary Cancers in Patients Undergoing Tumor-Normal Sequencing Define Novel Associations

  2025-12-17

• Data from Germline Pathogenic Variants Impact Clinicopathology of Advanced Lung Cancer

  2025-11-26

• Supplementary Data from Germline Pathogenic Variants Impact Clinicopathology of Advanced Lung Cancer

  2025-11-26

• Supplementary Data from Germline Pathogenic Variants Impact Clinicopathology of Advanced Lung Cancer

  2025-11-26

• Figure S2 from &lt;i&gt;NBN&lt;/i&gt; Pathogenic Germline Variants are Associated with Pan-Cancer Susceptibility and &lt;i&gt;In Vitro&lt;/i&gt; DNA Damage Response Defects

  2025-11-25